Fragment-based inhibitor discovery against β-lactamase

Future Medicinal Chemistry

Volumn 6, Issue 4, 2014, Pages 413-427

  Nichols, Derek A ^a   Renslo, Adam R ^b   Chen, Yu ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 9; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; DICARBOXYLIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; HYDROLASE; METALLO BETA LACTAMASE; SERINE BETA LACTAMASE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

BACTEROIDES FRAGILIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG HYDROLYSIS; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FRAGMENT BASED LEAD DISCOVERY; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BINDING SITES; CATALYTIC DOMAIN; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; HIGH-THROUGHPUT SCREENING ASSAYS; MOLECULAR DOCKING SIMULATION;

EID: 84896932244     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.10     Document Type: Review

References (115)

1. Testero SA, Fisher JF, Mobashery S. Beta-lactam antibiotics. In: Burger's Medicinal Chemistry, Drug Discovery and Development. Abraham DJ, Rotella DP (Eds). Wiley and Sons, NJ, USA, 259-404 (2010).
2. Llarrull LI, Testero SA, Fisher JF, Mobashery S. The future of the beta-lactams. Curr. Opin. Microbiol. 13(5), 551-557 (2010).
3. Frere JM. Beta-lactamases and bacterial resistance to antibiotics. Mol. Microbiol. 16(3), 385-395 (1995).
4. Taubes G. The bacteria fight back. Science 321(5887), 356-361 (2008).
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39(6), 1211-1233. (1995).
6. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8(4), 557-584 (1995).
7. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105(2), 395-424 (2005).
8. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48(1), 1-14 (2004).
9. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. J. Mol. Biol. 348(2), 349-362. (2005).
10. Chen Y, Shoichet B, Bonnet R. Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases. J. Am. Chem. Soc. 127(15), 5423-5434. (2005).
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14(4), 933-951 (2001).
12. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7(5), 459-469 (2007).
13. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54(1), 565-569 (2010).
14. Patel G, Bonomo RA. Status report on carbapenemases: challenges and prospects. Expert Rev. Anti Infect. Ther. 9(5), 555-570 (2012).
15. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist. Updat. 9(3), 142-156 (2006).
16. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160-201 (2010).
17. Bennett PM, Chopra I. Molecular basis of beta-lactamase induction in bacteria. Antimicrob. Agents Chemother. 37(2), 153-158 (1993).
18. Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell 88, 823-832 (1997).
19. Petrosino J, Cantu C 3rd, Palzkill T. Beta-lactamases: protein evolution in real time. Trends Microbiol. 6(8), 323-327 (1998).
20. Pages JM, Lavigne JP, Leflon-Guibout V et al. Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PloS ONE 4(3), e4817 (2009).
21. Ehmann DE, Jahic H, Ross PL et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl Acad. Sci. USA 109(29), 11663-11668 (2012).
22. Lahiri SD, Mangani S, Durand-Reville T et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob. Agents Chemother. 57(6), 2496-2505 (2013).
23. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against class A, C, and D beta-lactamases. J. Biol. Chem. 288(39), 27960-27971 (2013).
24. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob. Agents Chemother. 57(6), 2620-2630 (2013).
25. Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J. Antimicrob. Chemother. 68(8), 1825-1831 (2013).
26. Rahil J, Pratt RF. Phosphonate monoester inhibitors of class A beta-lactamases. Biochem. J. 275(Pt 3), 793-795 (1991).
27. Drawz SM, Babic M, Bethel CR et al. Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49(2), 329-340 (2010).
28. Eidam O, Romagnoli C, Dalmasso G et al. Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proc. Natl. Acad Sci. USA 109(43), 17448-17453 (2012).
29. Wyrembak PN, Babaoglu K, Pelto RB, Shoichet BK, Pratt RF. O-aryloxycarbonyl hydroxamates: new beta-lactamase inhibitors that cross-link the active site. J. Am. Chem. Soc. 129(31), 9548-9549 (2007).
30. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1), 29-40 (2007).
31. Babaoglu K, Simeonov A, Irwin JJ et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem. 51(8), 2502-2511. (2008).
32. Renslo AR. Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev. Anti Infect. Ther. 8(5), 565-574 (2010).
33. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J. Med. Chem. 51(7), 1981-1990 (2008).
34. O'shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51(10), 2871-2878 (2008).
35. Hert J, Irwin JJ, Laggner C, Keiser MJ, Shoichet BK. Quantifying biogenic bias in screening libraries. Nat. Chem. Biol. 5(7), 479-483 (2009).
36. Fink T, Reymond JL. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 47(2), 342-353 (2007).
37. Bohacek RS, Mcmartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16(1), 3-50 (1996).
38. Jhoti H, Williams G, Rees DC, Murray CW. The 'rule of three' for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discov. 12(8), 644 (2013).
39. Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3(8), 660-672. (2004).
40. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6(3), 211-219 (2007).
41. Schulz MN, Hubbard RE. Recent progress in fragment-based lead discovery. Curr. Opin. Pharmacol. 9(5), 615-621 (2009).
42. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
43. Pellecchia M, Bertini I, Cowburn D et al. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov. 7(9), 738-745. (2008).
44. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using x-ray crystallography. J. Med. Chem. 48(2), 403-413. (2005).
45. Sweeney ZK, Acharya S, Briggs A et al. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg. Med. Chem. Lett. 18(15), 4348-4351. (2008).
46. Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51(25), 4990-5003 (2012).
47. Baker M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12(1), 5-7 (2013).
48. Powers RA, Morandi F, Shoichet BK. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure 10(7), 1013-1023 (2002).
49. Horn JR, Shoichet BK. Allosteric inhibition through core disruption. J. Mol. Biol. 336(5), 1283-1291 (2004).
50. Toney JH, Hammond GG, Fitzgerald PM et al. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J. Biol. Chem. 276(34), 31913-31918 (2001).
51. Toney JH, Fitzgerald PM, Grover-Sharma N et al. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. Chem. Biol. 5(4), 185-196 (1998).
52. Hiraiwa Y, Morinaka A, Fukushima T, Kudo T. Metallo-beta-lactamase inhibitory activity of phthalic acid derivatives. Bioorg. Med. Chem. Lett. 19(17), 5162-5165 (2009).
53. Moloughney JG, D Thomas J, Toney JH. Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol. Lett. 243(1), 65-71 (2005).
54. Minond D, Saldanha SA, Spicer T et al. HTS assay for discovery of novel metallo-beta-lactamase (MBL) inhibitors. Probe Reports from the NIH Molecular Libraries Program [Internet] (2010).
55. Sun Q, Law A, Crowder MW, Geysen HM. Homo-cysteinyl peptide inhibitors of the L1 metallo-beta-lactamase, and SAR as determined by combinatorial library synthesis. Bioorg. Med. Chem. Lett. 16(19), 5169-5175 (2006).
56. Lienard BM, Huting R, Lassaux P, Galleni M, Frere JM, Schofield CJ. Dynamic combinatorial mass spectrometry leads to metallo-beta-lactamase inhibitors. J. Med. Chem. 51(3), 684-688 (2008).
57. Minond D, Saldanha SA, Subramaniam P et al. Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorg. Med. Chem. 17(14), 5027-5037 (2009).
58. Concha NO, Janson CA, Rowling P et al. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry 39(15), 4288-4298 (2000).
59. Zhang H, Hao Q. Crystal structure of NDM-1 reveals a common beta-lactam hydrolysis mechanism. FASEB J. 25(8), 2574-2582 (2011).
60. King DT, Worrall LJ, Gruninger R, Strynadka NC. New Delhi metallo-beta-lactamase: structural insights into beta-lactam recognition and inhibition. J. Am. Chem. Soc. 134(28), 11362-11365 (2012).
61. Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat. Chem. Biol. 5(5), 358-364 (2009).
62. Nichols DA, Jaishankar P, Larson W et al. Structure-based design of potent and ligand-efficient inhibitors of CTX-M Class A beta-lactamase. J. Med. Chem. 55(5), 2163-2172 (2012).
63. Teotico DG, Babaoglu K, Rocklin GJ, Ferreira RS, Giannetti AM, Shoichet BK. Docking for fragment inhibitors of AmpC beta-lactamase. Proc. Natl Acad. Sci. USA 106(18), 7455-7460 (2009).
64. Vella P, Hussein WM, Leung EW et al. The identification of new metallo-beta-lactamase inhibitor leads from fragment-based screening. Bioorg. Med. Chem. Lett. 21(11), 3282-3285 (2011).
65. Faridoon, Hussein WM, Vella P et al. 3-mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-beta-lactamase inhibitors. Bioorg. Med. Chem. Lett. 22(1), 380-386 (2012).
66. Murray CW, Blundell TL. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 20(4), 497-507 (2010).
67. Minasov G, Wang X, Shoichet BK. An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J. Am. Chem. Soc. 124(19), 5333-5340 (2002).
68. Chen Y, Bonnet R, Shoichet BK. The acylation mechanism of CTX-M beta-lactamase at 0.88 Angstrom resolution. J. Am. Chem. Soc. 129(17), 5378-5380. (2007).
69. Nukaga M, Mayama K, Hujer AM, Bonomo RA, Knox Jr. Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328(1), 289-301 (2003).
70. Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob. Agents Chemother. 52(10), 3725-3736 (2008).
71. Chen Y, Minasov G, Roth TA, Prati F, Shoichet BK. The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J. Am. Chem. Soc. 128(9), 2970-2976. (2006).
72. Chen Y, Pohlhaus DT. In silico docking and scoring of fragments. Drug Discov. Today Technol. 7(3), 149-156 (2010).
73. Desjarlais RL. Using computational techniques in fragment-based drug discovery. Methods Enzymol. 493, 137-155 (2011).
74. Murray CW, Verdonk ML, Rees DC. Experiences in fragment-based drug discovery. Trends Pharmacol. Sci. 33(5), 224-232 (2012).
75. Giannetti AM. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol. 493, 169-218 (2011).
76. Lepre CA. Practical aspects of NMR-based fragment screening. Methods Enzymol. 493, 219-239 (2011).
77. Irwin JJ, Shoichet BK. ZINC -a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45(1), 177-182. (2005).
78. Fast W, Sutton LD. Metallo-beta-lactamase: inhibitors and reporter substrates. Biochim. Biophys. Acta 1834(8), 1648-1659 (2013).
79. Van Berkel SS, Brem J, Rydzik AM et al. Assay platform for clinically relevant metallo-beta-lactamases. J. Med. Chem. 56(17), 6945-6953 (2013).
80. Meng E, Shoichet Bk, Kuntz ID. Automated docking with grid-based energy evaluation. J. Comput. Chem. 13, 505-524 (1992).
81. Lorber DM, Udo MK, Shoichet BK. Protein-protein docking with multiple ligand residue conformations and multiple residue identities. Protein Sci. 11, 1393-1408 (2002).
82. Jacoby GA. AmpC beta-lactamases. Clin. Microbiol. Rev. 22(1), 161-182, (2009).
83. Pai H, Kang CI, Byeon JH et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(10), 3720-3728 (2004).
84. Caselli E, Powers RA, Blasczcak LC, Wu CY, Prati F, Shoichet BK. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases. Chem. Biol. 8(1), 17-31. (2001).
85. Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40(31), 9207-9214. (2001).
86. Morandi F, Caselli E, Morandi S et al. Nanomolar inhibitors of AmpC beta-lactamase. J. Am. Chem. Soc. 125(3), 685-695 (2003).
87. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. Bioorg. Med. Chem. 16(3), 1195-1205 (2008).
88. Babaoglu K, Shoichet BK. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2(12), 720-723 (2006).
89. Leonard DA, Bonomo RA, Powers RA. Class D beta-lactamases: a reappraisal after five decades. Acc. Chem. Res. 46(11), 2407-2415 (2013).
90. Beck J, Vercheval L, Bebrone C, Herteg-Fernea A, Lassaux P, Marchand-Brynaert J. Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg. Med. Chem. Lett. 19(13), 3593-3597 (2009).
91. Docquier JD, Benvenuti M, Calderone V et al. Crystal structure of the narrow-spectrum OXA-46 class D beta-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob. Agents Chemother. 54(5), 2167-2174 (2010).
92. Beck J, Sauvage E, Charlier P, Marchand-Brynaert J. 2-aminopropane-1,2,3- tricarboxylic acid: synthesis and co-crystallization with the class A beta-lactamase BS3 of Bacillus licheniformis. Bioorg. Med. Chem. Lett. 18(13), 3764-3768 (2008).
93. Palzkill T. Metallo-beta-lactamase structure and function. Ann. NY Acad. Sci. 1277, 91-104 (2013).
94. King DT, Strynadka NC. Targeting metallo-beta-lactamase enzymes in antibiotic resistance. Future Med. Chem. 5(11), 1243-1263 (2013).
95. Irwin JJ, Raushel FM, Shoichet BK. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44(37), 12316-12328 (2005).
96. Wachino J, Yamaguchi Y, Mori S, Kurosaki H, Arakawa Y, Shibayama K. Structural insights into the subclass B3 metallo-beta-lactamase SMB-1 and the mode of inhibition by the common metallo-beta-lactamase inhibitor mercaptoacetate. Antimicrob. Agents Chemother. 57(1), 101-109 (2013).
97. Garcia-Saez I, Hopkins J, Papamicael C et al. The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, d-captopril. J. Biol. Chem. 278(26), 23868-23873 (2003).
98. Mollard C, Moali C, Papamicael C et al. Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases: kinetic and spectroscopic studies. J. Biol. Chem. 276(48), 45015-45023 (2001).
99. Lienard BM, Garau G, Horsfall L et al. Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. Org. Biomol. Chem. 6(13), 2282-2294 (2008).
100. Kurosaki H, Yamaguchi Y, Yasuzawa H, Jin W, Yamagata Y, Arakawa Y. Probing, inhibition, and crystallographic characterization of metallo-beta-lactamase (IMP-1) with fluorescent agents containing dansyl and thiol groups. ChemMedChem 1(9), 969-972 (2006).
101. Hussein WM, Fatahala SS, Mohamed ZM et al. Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-beta-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Chem. Biol. Drug Des. 80(4), 500-515 (2012).
102. Schlesinger SR, Bruner B, Farmer PJ, Kim SK. Kinetic characterization of a slow-binding inhibitor of Bla2: thiomaltol. J. Enzyme Inhib. Med. Chem. 28(1), 137-142 (2013).
103. Lassaux P, Hamel M, Gulea M et al. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J. Med. Chem. 53(13), 4862-4876 (2010).
104. Horsfall LE, Garau G, Lienard BM et al. Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila. Antimicrob. Agents Chemother. 51(6), 2136-2142 (2007).
105. Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 54(9), 3625-3629 (2010).
106. Livermore DM, Mushtaq S, Morinaka A, Ida T, Maebashi K, Hope R. Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J. Antimicrob. Chemother. 68(1), 153-158 (2013).
107. Feng L, Yang KW, Zhou LS et al. N-heterocyclic dicarboxylic acids: broad-spectrum inhibitors of metallo-beta-lactamases with co-antibacterial effect against antibiotic-resistant bacteria. Bioorg. Med. Chem. Lett. 22(16), 5185-5189 (2012).
108. Walter MW, Felici A, Galleni M et al. Trifluoromethyl alcohol and ketone inhibitors of metallo-beta-lactamases. Bioorg. Med. Chem. Lett. 6, 2455-2458 (1996).
109. Walter MW, Adlington RM, Baldwin JE, Schofield CJ. Synthesis of metallo-beta-lactamase inhibitors. Tetrahedron 53, 7275-7290 (1997).
110. Docquier JD, Benvenuti M, Calderone V et al. High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. Antimicrob. Agents Chemother. 54(10), 4343-4351 (2010).
111. Fitzgerald PM, Wu JK, Toney JH. Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution. Biochemistry 37(19), 6791-6800 (1998).
112. Chen P, Horton LB, Mikulski RL et al. 2-substituted 4,5-dihydrothiazole- 4-carboxylic acids are novel inhibitors of metallo-beta-lactamases. Bioorg. Med. Chem. Lett. 22(19), 6229-6232 (2012).
113. Hammond GG, Huber JL, Greenlee ML et al. Inhibition of IMP-1 metallo-beta-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. FEMS Microbiol. Lett. 179(2), 289-296 (1999).
114. Garcia-Saez I, Mercuri PS, Papamicael C et al. Three-dimensional structure of FEZ-1, a monomeric subclass B3 metallo-beta-lactamase from Fluoribacter gormanii, in native form and in complex with d-captopril. J. Mol. Biol. 325(4), 651-660 (2003).
115. Heinz U, Bauer R, Wommer S et al. Coordination geometries of metal ions in d-or l-captopril-inhibited metallo-beta-lactamases. J. Biol. Chem. 278(23), 20659-20666 (2003).